Serum prostate-specific antigen values for the prediction of clinical stage and prognosis in patients with prostate cancer: An analysis of 749 cases

International Journal of Urology

Volumn 3, Issue 6, 1996, Pages 462-467

  Kuriyama, Manabu ^a,b   Obata, Koji ^a   Miyagawa, Yoshimasa ^a   Nishikawa, Eiji ^a   Koide, Takuya ^a   Takeda, Akihisa ^a   Komeda, Yoshinori ^a   Kanbayashi, Tomoyuki ^a   Nakano, Masaru ^a   Miyake, Koji ^a  

^a Japanese Urological Association   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Assay method; Prediction of stages and prognosis; Prostate cancer; PSA; Tumor registry

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

EID: 8044253434     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00577.x     Document Type: Article

References (25)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
2. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
3. Brawer NK. Prostate specific antigen. A review. Acta Oncol 1991;301:161-168.
4. Akimoto S, Masai M, Kitagawa K, Shimazaki J. Tumor marker in the urological tumor: its reliability and limitation: PSA. Urol Surg 1991;4:1065-1072.
5. Kuriyama M. Prostate-specific antigen as a tumor marker in prostate cancer. Int J Urol 1994;1:99-113.
6. Kuriyama M, Kawada Y. Clinical significance of PSA in diagnosis of prostate cancer. Rinsyo Hinyoukika 1994;48:277-288.
7. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-752.
8. Haapiainen PK, Permi EJ, Panniko SA, Voutilaine PE, Liewendahl K, Stennman UH, Alfthan OS. Prostate tumor markers as an aid in the staging of prostatic cancer. Br J Urol 1990;65:264-267.
9. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determination before and after radical prostatectomy. J Urol 1989;141:873-879.
10. Kuriyama M, Wang MC, Lee CL, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981; 41:3874-3878.
11. Akimoto S, Akakura K, Masai M, Isaka S, Shimazaki J. Changes in prostatic acid phosphatase, γ-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer. Acta Urol Jpn 1990;36:783-791.
12. Shinoda I. Clinical studies on tumor markers for monitoring prostate cancer patients: the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and γ-seminoprotein. J Jpn Soc Cancer Ther 1990;25:2627-2639.
13. Arai Y, Yoshiki T, Oishi K, Takeuchi H, Yoshida O. The role of prostatic specific antigen in monitoring prostatic cancer and its prognostic importance. Urol Res 1990;18:331-336.
14. Japanese Urological Association and the Japanese Pathological Society. General Rules for Clinical and Pathological Studies on Prostate Cancer. 2nd ed. Tokyo: Kanehara, 1992.
15. Kuriyama M, Shinoda I, Takeuchi T, Ban Y, Kawada Y, Nishiura, Yoshiki T, Okada O, Hamami G, Kamidono S, Mita T, Terasoma K. Clinical evaluation of prostate-specific antigen with an EIA: a co-operative study. Nishinihon J Urol 1987;49:1431-1438.
16. Miki M, Machida T, Yanagisawa M, Yoshida S, Yamazaki H, Konda N, Azuma Y, Takahashi T, Kurauchi Y. Clinical evaluation of serum prostatic specific antigen measurement by radioimmunoassay. Jpn J Urol 1984;75:1982-1988.
17. Kuriyama M, Akimoto S, Akaza H, Arai Y, Usami M, Imai K, Tanaka Y, Yamazaki H, Kawada Y, Koiso K, Yoshida O, Kotake T, Yamanaka H, Machida T, Aso Y, Shimazaki J. Comparison of various assay systems for prostate-specific antigen standardization. Jpn J Clin Oncol 1992;22:393-399.
18. Obata K, Kuriyama M, Fujita K, Sakai S, Okishiho N, Sakagami S, Higashino I, Miyake K. Clinical analysis of 683 prostatic cancer patients in the Tokai Urological Cancer Registry. Acta Urol Jpn 1996; 42:503-507.
19. Chybowski FM, Larson-Keller JJ, Bergstralh WJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991;145:313-318.
20. Arai Y, Yoshiki T, Yamabe H, Yoshida Y. Value of prostate-specific antigen measurement in predicting lymph node involvement in prostatic cancer. Urol Int 1990;45:356-360.
21. Kuriyama M, Kawada Y. Can PSA predict staging of prostate cancer? In: Murphy G, Khoury S, Chatelan C, Denis L (eds). Proceedings of the 4th International Symposium on Recent Advances in Urological Cancer, Diagnosis and Treatment. Channel Islands: Scientific Communication International, 1995;110-114.
22. Killian CS, Yang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, Slack NH, Papsidero LD, Murphy GP, Chu TM, the Investigators of the National Prostatic Cancer Project. Prognostic importance of prostate-specific antigen in patients with stage B2 to D1 prostate cancer. Cancer Res 1985;45:886-891.
23. Matzkin H, Eber P, Tadd B, van der Zwaag R, Soloway MS. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostate cancer. Cancer 1992;70:2302-2309.
24. Arai Y, Yoshiki T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990;144:1415-1419.
25. Kuriyama M, Yamamoto N, Shinoda I, Kawada Y, Akimoto S, Shimazaki J. Clinical evaluation of TANDEM PSA in Japanese cases and comparison with other methods. Act Urol Jpn 1995;41:39-46.